| Bioactivity | hTG2 inhibitor VA4 (compound VA4) is an irreversible Type 2 transglutaminase (TG2) inhibitor. hTG2 inhibitor VA4 reacts exclusively at the TG2 transamidase site, inhibits both transamidase and GTP-binding activities[1]. |
| Invitro | hTG2 inhibitor VA4 (compound VA4) 抑制ECS细胞（表皮癌干细胞）球体形成和侵袭[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> hTG2 inhibitor VA4 相关抗体: |
| CAS | 2088001-23-2 |
| Formula | C33H41N5O6S |
| Molar Mass | 635.77 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kerr C, et al. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. Oncogene. 2017 May 25;36(21):2981-2990. |
hTG2 inhibitor VA4
CAS: 2088001-23-2 F: C33H41N5O6S W: 635.77
hTG2 inhibitor VA4 (compound VA4) is an irreversible Type 2 transglutaminase (TG2) inhibitor. hTG2 inhibitor VA4 reacts
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.